Poolbeg Pharma PLC (AIM:POLB) Jeremy Skillington joins Proactive London to talk about their new deal - using a state of the art artificial intelligence tool to find new drug targets for respiratory syncytial virus (RSV).
Under the terms of a deal with OneThree Biotech, it will screen for putative treatments that focus in on the immune-response pathways, have a higher probability of clinical success and have the potential to prevent and/or treat infectious diseases.
Skillington says their 'OneThree Biotech's AI analysis tools will allow us to break new ground in data-driven drug discovery, by allowing us to evaluate and interrogate human challenge trial data like never before'.